Free EMR Newsletter Want to receive the latest news on EMR, Meaningful Use, ARRA and Healthcare IT sent straight to your email? Join thousands of healthcare pros who subscribe to EMR and EHR for FREE!

AI Project Could Prevent Needless Blindness

Posted on January 11, 2018 I Written By

Anne Zieger is veteran healthcare consultant and analyst with 20 years of industry experience. Zieger formerly served as editor-in-chief of FierceHealthcare.com and her commentaries have appeared in dozens of international business publications, including Forbes, Business Week and Information Week. She has also contributed content to hundreds of healthcare and health IT organizations, including several Fortune 500 companies. Contact her at @ziegerhealth on Twitter or visit her site at Zieger Healthcare.

At this point, you’re probably sick of hearing about artificial intelligence and the benefits it may offer as a diagnostic tool. Even so, there are still some AI stories worth telling, and the following is one of them.

Yes, IBM Watson Health recently had a well-publicized stumble when it attempted to use “cognitive computing” to detect cancer, but that may have more to do with the fact that Watson was under so much pressure to produce results quickly with something that could’ve taken a decade to complete. Other AI-based diagnostic projects seem to be making far more progress.

Consider the following, for example. According to a story in WIRED magazine, Google is embarking on a project which could help eye doctors detect diabetic retinopathy and prevent blindness, basing its efforts on technologies it already has in-house.

The tech giant reported last year that it had trained image recognition algorithms to detect tiny aneurysms suggesting that the patient is in the early stages of retinopathy. This system uses the same technology that allows Google’s image search photo and photo storage services to discriminate between various objects and people.

To take things to the next step, Google partnered with the Aravind Eye Care System, a network of eye hospitals based in India. Aravind apparently helped Google develop the retinal screening system by contributing some of the images it already had on hand to help Google develop its image parsing algorithms.

Aravind and Google have just finished a clinical study of the technology in India with Aravind. Now the two are working to bring the technology into routine use with patients, according to a Google executive who spoke at a recent conference.

The Google exec, Lily Peng, who serves as a product manager with the Google Brain AI research group, said that these tools could help doctors to do the more specialized work and leave the screening to tools like Google’s. “There is not enough expertise to go around,” she said. “We need to have a specialist working on treating people who are sick.”

Obviously, we’ll learn far more about the potential of Google’s retinal scanning tech once Aravind begins using it on patients every day. In the meantime, however, one can only hope that it emerges as a viable and safe tool for overstressed eye doctors worldwide. The AI revolution may be overhyped, but projects like this can have an enormous impact on a large group of patients, and that can’t be bad.

IBM Works To Avoid FDA Oversight For Its Watson Software

Posted on October 25, 2017 I Written By

Anne Zieger is veteran healthcare consultant and analyst with 20 years of industry experience. Zieger formerly served as editor-in-chief of FierceHealthcare.com and her commentaries have appeared in dozens of international business publications, including Forbes, Business Week and Information Week. She has also contributed content to hundreds of healthcare and health IT organizations, including several Fortune 500 companies. Contact her at @ziegerhealth on Twitter or visit her site at Zieger Healthcare.

I live in DC, where the fog of politics permeates the air. Maybe that’s given me more of a taste for political inside baseball than most. But lest the following story seems to fall into that category, put that aside – it actually involves some moves that could affect all of us.

According to Stat News, IBM has been lobbying hard to have its “cognitive computing” (read: AI) superbrain Watson exempt from FDA oversight. Earlier this year, eight of its employees were registered to lobby Congress on this subject, the site reports.

Through its Watson Health subsidiary, IBM has joined the crowded clinical decision support arena, a software category which could face FDA regulation soon.

Historically, the agency has dragged its heels on issuing CDS review guidelines. In fact, as of late last year, one-third of CDS developers were abandoning product development due to their uncertainty about the outcome of the FDA’s deliberations, according to a survey by the Clinical Decision Support Alliance.

Now, the agency is poised to issue new guidelines clarifying which software types will be reviewed and which will be exempt under the provisions of the 21st Century Cures Act. Naturally, IBM wants Watson to fall into the latter category.

According to Stat News, IBM spent $26.4 million lobbying Congress between 2013 and June 2017. While IBM didn’t disclose how much of that spent on the CDS regulation issue, it did tell the site that it was “one of many organizations, including patient and physician groups, that supported a common sense regulatory distinction between low-risk software and inherently higher-risk technologies.”

IBM also backed a bill known as the Software Act, which was opposed by the FDA office in charge of device regulation but backed enthusiastically by many software makers. The bill, which was first introduced in 2013, specified that health software would be exempted from FDA regulation unless it provided patient-specific recommendations and posed a significant risk to patient safety. It didn’t pass.

Now, executives with the computing giant will soon learn what fruit their lobbying efforts bore. The FDA said it intends to issue guidance documents explaining how it will implement the exemptions in the 21st Century Cures Act during the first quarter of next year.

No matter what direction it takes, the new FDA guidance is likely to be controversial, as key regulatory language in the 21st Century Cures Act remains open to interpretation. The law includes exemptions for advisory systems, but only if it’s they allow “health care professional to independently review the basis for such recommendations.”  Lawyers representing software makers told Stat News that no one’s sure what the phrase “independently review the basis” means, and that’s a big deal.

Regardless, it’s the FDA’s job to figure out what key provisions in the new law mean. In the meantime, waiting will be a bit stressful even for giants like IBM. Big Blue has made a huge bet on Watson Health, and if the FDA doesn’t rule in is favor, it might need a new strategy.